Combination of Subtherapeutic Doses of Tretazicar and Liposomal Amphotericin B Suppresses and Cures
CB1954
combination treatment
cutaneous leishmaniasis
tretazicar
Journal
ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580
Informations de publication
Date de publication:
12 02 2021
12 02 2021
Historique:
pubmed:
3
2
2021
medline:
24
6
2021
entrez:
2
2
2021
Statut:
ppublish
Résumé
Cutaneous leishmaniasis (CL) is the most common form of leishmaniasis affecting human populations, yet CL remains largely ignored in drug discovery programs. CL causes disfiguring skin lesions and often relapses after "clinical cure" using existing therapeutics. To expand the pool of anti-CL lead candidates, we implemented an integrated screening platform comprising three progressive
Identifiants
pubmed: 33529014
doi: 10.1021/acsinfecdis.0c00886
doi:
Substances chimiques
Antiprotozoal Agents
0
Aziridines
0
liposomal amphotericin B
0
tretazicar
7865D5D01M
Amphotericin B
7XU7A7DROE
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM